Skip to main content
. 2021 Sep 1;9(9):1144. doi: 10.3390/healthcare9091144

Table 2.

CSU treatment during COVID-19 mild or moderate-severe type of disease, represented as percent and number of patients.

CSU Treatment Mild
COVID-19 Infection
(n = 21)
Moderate/Severe COVID-19 Infection
(n = 51)
Single dose AH1 14.2% (3) 1.9% (1)
Double dose AH1 42.8% (9) 29.4% (15)
Four-fold dose AH1 33.3% (7) 39.1% (20)
Omalizumab 0% (0) 19.6% (10)
Cyclosporine 0% (0) 0% (0)
Prednisone 0% (0) 3.9% (2)
No treatment 9.7% (2) 9.1% (5)